Daxor on Monday highlighted the results of studies from Duke Heart validating the utility of the firm's BVA-100 diagnostic blood test in optimizing the therapeutic management of heart failure patients.
The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022, which took place from September 30 through October 3 in Washington, DC.
The studies used Daxor’s BVA-100 test in patients with an implanted pulmonary monitor; results demonstrated that it measured actual blood volume with an accuracy of 98%.
Effective blood volume management is critical in the treatment of heart failure.
“The clinical implications are significant, as managing patients for cardiovascular congestion based on pressure measures alone might not be sufficient," Dr. Marat Fudim, principal investigator and an assistant professor of medicine at Duke University School of Medicine, said in a statement. "Pressure measures provide complementary but different information. Pressure is not volume.”
One of the studies demonstrated a lack of correlation between the pressure metric and blood volume, even for those with overall higher pressures and blood volume. The other study highlighted sex-specific differences in heart failure patients. The findings showed that men had higher blood volume and greater total blood volume percent deviation than women with similar pressure readings, as well as discordance between pressure and volume measures in both men and women.
